title: Dynamics of the cytotoxic T cell response to a model of acute viral infection.
abstract: A detailed characterization of the dynamics and breadth of the immune response to an acute viral infection, as well as the determinants of recruitment to immunological memory, can greatly contribute to our basic understanding of the mechanics of the human immune system and can ultimately guide the design of effective vaccines. In addition to neutralizing antibodies, T cells have been shown to be critical for the effective resolution of acute viral infections. We report the first in-depth analysis of the dynamics of the CD8(+) T cell repertoire at the level of individual T cell clonal lineages upon vaccination of human volunteers with a single dose of YF-17D. This live attenuated yellow fever virus vaccine yields sterile, long-term immunity and has been previously used as a model to understand the immune response to a controlled acute viral infection. We identified and enumerated unique CD8(+) T cell clones specifically induced by this vaccine through a combined experimental and statistical approach that included high-throughput sequencing of the CDR3 variable region of the T cell receptor β-chain and an algorithm that detected significantly expanded T cell clones. This allowed us to establish that (i) on average, ∼ 2,000 CD8(+) T cell clones were induced by YF-17D, (ii) 5 to 6% of the responding clones were recruited to long-term memory 3 months postvaccination, (iii) the most highly expanded effector clones were preferentially recruited to the memory compartment, and (iv) a fraction of the YF-17D-induced clones could be identified from peripheral blood lymphocytes solely by measuring clonal expansion.
  
  
  OBJECTIVE
  The exhaustive investigation of pathogen-induced effector T cells is essential to accurately quantify the dynamics of the human immune response. The yellow fever vaccine (YFV) has been broadly used as a model to understand how a controlled, self-resolving acute viral infection induces an effective and long-term protective immune response. Here, we extend this previous work by reporting the identity of activated effector T cell clones that expand in response to the YFV 2 weeks postvaccination (as defined by their unique T cell receptor gene sequence) and by tracking clones that enter the memory compartment 3 months postvaccination. This is the first study to use high-throughput sequencing of immune cells to characterize the breadth of the antiviral effector cell response and to determine the contribution of unique virus-induced clones to the long-lived memory T cell repertoire. Thus, this study establishes a benchmark against which future vaccines can be compared to predict their efficacy.
authors: Adaptive Biotechnologies, Seattle, Washington, USA.
authors: William S
authors: WS
authors: DeWitt
authors: Adaptive Biotechnologies, Seattle, Washington, USA.
authors: Ryan O
authors: RO
authors: Emerson
authors: Fred Hutchinson Cancer Research Center, Seattle, Washington, USA University of Washington, Seattle, Washington, USA.
authors: Paul
authors: P
authors: Lindau
authors: Adaptive Biotechnologies, Seattle, Washington, USA.
authors: Marissa
authors: M
authors: Vignali
authors: Adaptive Biotechnologies, Seattle, Washington, USA.
authors: Thomas M
authors: TM
authors: Snyder
authors: Adaptive Biotechnologies, Seattle, Washington, USA.
authors: Cindy
authors: C
authors: Desmarais
authors: Adaptive Biotechnologies, Seattle, Washington, USA.
authors: Catherine
authors: C
authors: Sanders
authors: Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
authors: Heidi
authors: H
authors: Utsugi
authors: Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
authors: Edus H
authors: EH
authors: Warren
authors: Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
authors: Juliana
authors: J
authors: McElrath
authors: Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
authors: Karen W
authors: KW
authors: Makar
authors: University of Washington, Seattle, Washington, USA.
authors: Anna
authors: A
authors: Wald
authors: Adaptive Biotechnologies, Seattle, Washington, USA Fred Hutchinson Cancer Research Center, Seattle, Washington, USA hrobins@fhcrc.org.
authors: Harlan S
authors: HS
authors: Robins
mesh_terms: D001483:Base Sequence; D019070:Cell Lineage / Q000276:immunology*; D005434:Flow Cytometry; D006801:Humans; D007156:Immunologic Memory / Q000276:immunology*; D008969:Molecular Sequence Data; D017422:Sequence Analysis, DNA; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000494:pharmacology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000494:pharmacology*; D014861:Washington; D015005:Yellow fever virus / Q000276:immunology*
chemical_list: D014613:Vaccines, Attenuated; D014765:Viral Vaccines
references: J Exp Med. 1997 Nov 3;186(9):1407-18
references: 9348298
references: Nature. 1994 Jun 23;369(6482):652-4
references: 7516039
references: J Immunol. 2009 Dec 15;183(12):7919-30
references: 19933869
references: Immunol Cell Biol. 2011 Mar;89(3):340-5
references: 21301482
references: Immunity. 2012 Jan 27;36(1):142-52
references: 22265676
references: Nat Immunol. 2011 Jun;12(6):509-17
references: 21739679
references: J Virol. 2008 Jun;82(12):6024-33
references: 18400851
references: Cell. 1988 Aug 12;54(4):473-84
references: 2456856
references: J Immunol. 2013 Mar 1;190(5):2150-8
references: 23338234
references: Nucleic Acids Res. 2015 Jan;43(Database issue):D413-22
references: 25378316
references: J Immunol. 2011 Jun 15;186(12):7039-49
references: 21555537
references: Immunity. 2013 Sep 19;39(3):496-507
references: 24054328
references: Cell. 2012 Sep 14;150(6):1249-63
references: 22980984
references: Curr Opin Immunol. 2013 Oct;25(5):653-9
references: 23993410
references: Eur J Immunol. 2012 Sep;42(9):2363-73
references: 22733156
references: Ther Adv Vaccines. 2013 Nov;1(4):144-52
references: 24757521
references: J Virol. 2006 Dec;80(24):12032-40
references: 17035327
references: Immunity. 2007 Sep;27(3):393-405
references: 17892848
references: J Exp Med. 2007 Jun 11;204(6):1405-16
references: 17535971
references: Nat Rev Immunol. 2009 Oct;9(10):741-7
references: 19763148
references: Science. 1995 Apr 7;268(5207):106-11
references: 7535476
references: Bioinformatics. 2004 Aug 4;20 Suppl 1:i379-85
references: 15262823
references: Immunity. 2008 May;28(5):710-22
references: 18468462
references: Nature. 2009 Jan 8;457(7226):196-9
references: 19005468
references: J Exp Med. 2006 Feb 20;203(2):413-24
references: 16461338
references: Immunity. 2002 Dec;17(6):757-68
references: 12479822
references: Immunity. 2003 Apr;18(4):549-59
references: 12705857
references: Immunity. 2007 Oct;27(4):670-84
references: 17950003
references: Immunity. 1998 Jun;8(6):683-91
references: 9655482
references: Mem Inst Oswaldo Cruz. 2005 May;100(3):331-7
references: 16113878
references: Blood. 2009 Nov 5;114(19):4099-107
references: 19706884
references: Nat Immunol. 2002 Jul;3(7):619-26
references: 12055624
references: Immunology. 2009 Sep;128(1 Suppl):e718-27
references: 19740333
references: Virology. 2002 Feb 1;293(1):151-63
references: 11853408
references: J Exp Med. 1998 Jul 6;188(1):71-82
references: 9653085
references: Immunity. 1998 Feb;8(2):177-87
references: 9491999
references: Nature. 1999 Oct 14;401(6754):708-12
references: 10537110
references: J Med Virol. 1998 Oct;56(2):159-67
references: 9746073
references: Clin Cancer Res. 2014 Sep 1;20(17):4540-8
references: 24970842
references: J Virol. 2013 Dec;87(23):12794-804
references: 24049183
references: Nature. 1992 Jan 16;355(6357):224-30
references: 1309938